Estrogen-induced breast cancer, therapeutical approaches and the role of melatonin in treatment [Östrojenle İndüklenen meme kanseri, tedavi yaklaşımları ve melatoninin tedavideki rolü]
Küçük Resim Yok
Tarih
2019
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Hacettepe University, Faculty of Pharmacy
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Breast cancer is the second cause of death among female cancers and its incidence is increasing rapidly. Endogen estrogens and xenoestrogens are involved in the initiation and progression of breast cancer via two complementary pathways; they can increase cell proliferation via binding to estrogen receptor and their reactive quinone metabolites can induce oxidative DNA damage. Adjuvant treatment of hormone-dependent breast cancer aims to eliminate the effect of estrogens either by using selective estrogen receptor modulators (SERM) or selective estrogen enzyme modulators (SEEM). Adverse effects of current drugs and development of resistance to therapy promotes investigation of new therapeutic agents against breast cancer. Melatonin, an indolic hormone, is known to be beneficial in breast cancer via estrogen receptor mediated effects and inhibition of aromatase. Furthermore melatonin is reported to increase effectiveness and reduce adverse effects of the conventional breast cancer therapy. However short half-life and low bioavailibility limits its therapeutic use. Therefore synthesizing new and more effective melatonin analogues with longer half lives is suggested to improve success of the therapy. © 2019, Hacettepe University, Faculty of Pharmacy. All rights reserved.
Açıklama
Anahtar Kelimeler
Breast cancer, Estrogen, Melatonin, SEEM, SERM
Kaynak
Hacettepe University Journal of the Faculty of Pharmacy
WoS Q Değeri
Scopus Q Değeri
Q4
Cilt
39
Sayı
2
